Shire's Vyvanse nabs FDA approval for binge-eating disorder
- Vyvanse (lisdexamfetamine), which was initially approved for treatment of ADHD, is now FDA-approved for treatment of binge-eating disorder (BED), based on strong phase III data showing that it is superior to placebo in terms of curbing BED.
- Vyvanse has already booked strong sales, with $354.9 million in sales in Q3 2104.
- Roughly 2.8 million Americans have BED.
Binge eating disorder causes serious health problems and can contribute to difficulties with home, work, and social life, according to Mitchell Mathis, director of the Division of Psychiatry Products in the FDA's Center for Drug Evaluation and Research, as reported in Pharma Times.
- Pharma Times FDA okays Shire ADHD drug Vyvanse for binge eating